Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib (GIDEON) study

International Journal of Clinical Practice

Volumn 64, Issue 8, 2010, Pages 1034-1041

  Lencioni, R ^a   Marrero, J ^b   Venook, A ^c   Ye, S L ^d   Kudo, M ^e  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FUDAN UNIVERSITY   (China)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; HUMANS; LIVER NEOPLASMS; PATIENT SELECTION; PROSPECTIVE STUDIES; PYRIDINES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77953820596     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02414.x     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 2576.
3. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
4. Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009 101 : 1348 1355.
5. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006 23 : 1535 1547.
6. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 35 : 1164 1171.
7. Llovet JM, Real MI, Montañá X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002 359 : 1734 1739.
8. Llovet JM, Bruix J, for the Barcelona-Clinic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003 37 : 429 442.
9. National Comprehensive Cancer Network. NCCN Guidelines in Oncology 2009. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp (accessed April 2010).
10. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 359 : 378 390.
11. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 10 : 25 34.
12. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 24 : 4293 4300.
13. Furuse J, Ishii H, Nakachi K et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008 99 : 159 165.
14. Ligthelm RJ, Borzi V, Gumprecht J et al. Importance of observational studies in clinical practice. Clin Ther 2007 29 Spec No : 1284 1292.
15. Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007 147 : W163 94.
16. European Medicines Agency. Volume 9A of the Rules Governing Medicinal Products in the European Union. http://ec.europa.eu/enterprise/pharmaceuticals/ eudralex/vol-9/pdf/vol9a-09-2008.pdf (accessed April 2010).
17. Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008 2 : 453 462.
18. Saito H, Masuda T, Tada S et al. Hepatocellular carcinoma in Keio affiliated hospitals - diagnosis, treatment, and prognosis of this disease. Keio J Med 2009 58 : 161 175.
19. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009 10 : 425 434.
20. NCT00692770. Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma (STORM). http://clinicaltrials.gov/ct2/ show/NCT00692770?term=nct00692770&rank=1 (accessed April 2010).
21. NCT00855218. A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). http://clinicaltrials.gov/ct2/show/ NCT00855218?term=nct00855218&rank=1 (accessed April 2010).
22. NCT00494299. Phase III Study of BAY 43-9006 in Japanese Patients With Advanced Hepatocellular Carcinoma. http://clinicaltrials.gov/ct2/show/ NCT00494299?term=nct00494299&rank=1 (accessed April 2010).
23. NCT00901901. Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH). http://clinicaltrials.gov/ct2/show/NCT00901901?term=nct00901901&rank=1 (accessed April 2010).